Valrubicin

Valrubicin is a chemotherapy agent, inhibits TPA- and PDBu-induced PKC activation with IC50s of 0.85 and 1.25 μM, respectively, and has antitumor and antiinflammatory activity.

Product Specifications

CAS Number

[56124-62-0]

Product Name Alternative

AD-32

UNSPSC

12352005

Hazard Statement

H302, H340, H350, H360

Target

Antibiotic; PKC

Type

Reference compound

Related Pathways

Anti-infection; Epigenetics; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Valrubicin.html

Purity

99.60

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

CCCCC(OCC([C@]1(O)CC2=C(C(O)=C3C(C4=C(C(C3=C2O)=O)C=CC=C4OC)=O)[C@@H](O[C@H]5C[C@H](NC(C(F)(F)F)=O)[C@H](O)[C@H](C)O5)C1)=O)=O

Molecular Formula

C34H36F3NO13

Molecular Weight

723.64

Precautions

H302, H340, H350, H360

References & Citations

[1]Chuang LF, et al. Activation of human leukemia protein kinase C by tumor promoters and its inhibition by N-trifluoroacetyladriamycin-14-valerate (AD 32) . Biochem Pharmacol. 1992 Feb 18;43 (4) :865-72.|[2]Wani MK, et al. Rationale for intralesional valrubicin in chemoradiation of squamous cell carcinoma of the head and neck. Laryngoscope. 2000 Dec;110 (12) :2026-32.|[3]Hauge E, et al. Topical valrubicin application reduces skin inflammation in murine models. Br J Dermatol. 2012 Aug;167 (2) :288-95.